- Home
- CRSP vs CPRX Comparison
CRSP vs CPRX Comparison
Compare CRSP & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- CPRX
- Stock Information
- Founded
- CRSP 2013
- CPRX 2002
- Country
- CRSP Switzerland
- CPRX United States
- Employees
- CRSP N/A
- CPRX N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- CRSP Health Care
- CPRX Health Care
- Exchange
- CRSP Nasdaq
- CPRX Nasdaq
- Market Cap
- CRSP 3.4B
- CPRX 2.8B
- IPO Year
- CRSP 2016
- CPRX 2006
- Fundamental
- Price
- CRSP $37.77
- CPRX $22.52
- Analyst Decision
- CRSP Buy
- CPRX Strong Buy
- Analyst Count
- CRSP 19
- CPRX 7
- Target Price
- CRSP $74.35
- CPRX $32.29
- AVG Volume (30 Days)
- CRSP 2.4M
- CPRX 1.7M
- Earning Date
- CRSP 05-07-2025
- CPRX 05-07-2025
- Dividend Yield
- CRSP N/A
- CPRX N/A
- EPS Growth
- CRSP N/A
- CPRX 107.94
- EPS
- CRSP N/A
- CPRX 1.31
- Revenue
- CRSP $37,314,000.00
- CPRX $491,734,000.00
- Revenue This Year
- CRSP $51.35
- CPRX $15.17
- Revenue Next Year
- CRSP $282.16
- CPRX $9.61
- P/E Ratio
- CRSP N/A
- CPRX $17.19
- Revenue Growth
- CRSP N/A
- CPRX 23.49
- 52 Week Low
- CRSP $30.04
- CPRX $14.47
- 52 Week High
- CRSP $67.88
- CPRX $26.16
- Technical
- Relative Strength Index (RSI)
- CRSP 49.46
- CPRX 48.15
- Support Level
- CRSP $36.74
- CPRX $21.93
- Resistance Level
- CRSP $40.13
- CPRX $23.27
- Average True Range (ATR)
- CRSP 2.67
- CPRX 1.27
- MACD
- CRSP 0.72
- CPRX -0.14
- Stochastic Oscillator
- CRSP 76.62
- CPRX 50.60
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).